Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review

Nashiro, T; Yagi, Chiaki; Hirakawa, Makoto; Inamine, Morihiko; Nagai, Yutaka; Sakumoto, Kaoru; Tamaki, Wakana; Ogawa, Kazuhiko; Toita, Takafumi; Aoki, Yoichi

doi:10.1007/s10147-007-0758-7

Cited by 30 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nashiro and colleagues reported on a smaller retrospective series of 6 patients treated with cisplatin-based CRT, of whom 4 remained free of disease at 18, 23, 33 and 55 months, respectively. [14] Our current study, with 51 RT-only and 20 CRT patients, represents the largest series of chemoradiation compared to radiation only for patients with primary vaginal cancer treated at the same institution.…”

Section: Discussionmentioning

confidence: 99%

“…Studies published to date address the feasibility and outcomes of CRT for primary vaginal cancer, but have few patients and therefore comparisons to RT alone are limited [12], [13], [14]. In this study, we analyze and compare the clinical outcomes of patients with primary vaginal cancer treated at our institution with either definitive RT or with CRT.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Concurrent Chemoradiation for Vaginal Cancer

Miyamoto

Viswanathan

2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundIt is not known whether the addition of chemotherapy to radiation therapy improves outcomes in primary vaginal cancer. Here, we review clinical outcomes in patients with primary vaginal cancer treated with radiation therapy (RT) or concurrent chemoradiation therapy (CRT).MethodsSeventy-one patients with primary vaginal cancer treated with definitive RT with or without concurrent chemotherapy at a single institution were identified and their records reviewed. A total of 51 patients were treated with RT alone; 20 patients were treated with CRT. Recurrences were analyzed. Overall survival (OS) and disease-free survival (DFS) rates were estimated using the Kaplan-Meier method. Cox regression analysis was performed.ResultsThe median age at diagnosis was 61 years (range, 18–92 years) and the median follow-up time among survivors was 3.0 years. Kaplan-Meier estimates for OS and DFS differed significantly between the RT and CRT groups (3-yr OS = 56% vs. 79%, log-rank p = 0.037; 3-yr DFS = 43% vs. 73%, log-rank p = 0.011). Twenty-three patients (45%) in the RT group had a relapse at any site compared to 3 (15%) in the CRT group (p = 0.027). With regard to the sites of first relapse, 10 patients (14%) had local only, 4 (6%) had local and regional, 9 (13%) had regional only, 1 (1%) had regional and distant, and 2 (3%) had distant only relapse. On univariate analysis, the use of concurrent chemotherapy, FIGO stage, tumor size, and date of diagnosis were significant predictors of DFS. On multivariate analysis, the use of concurrent chemotherapy remained a significant predictor of DFS (hazard ratio 0.31 (95% CI, 0.10–0.97; p = 0.04)).ConclusionsVaginal cancer results in poor outcomes. Adequate radiation dose is essential to ensure curative management. Concurrent chemotherapy should be considered for vaginal cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Concurrent Chemoradiation for Vaginal Cancer

Miyamoto

Viswanathan

2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Nashiro et al [64] analyzed 6 patients who received EBRT and concomitant cisplatin, followed by intracavitary BT or boost EBRT with shrinking fields, up to a total radiation dose of 60-66 Gy. All the patients achieved a clinical complete response, and of these 4 patients were free of disease after a median time of 28 months, one patient developed a local failure after 12 months, and one patient died of disease after 24 months.…”

Section: Concurrent Chemoradiationmentioning

confidence: 99%

“…The standard treatment is radiotherapy, which utilizes external beam radiation [EBRT] and/or brachytherapy [BT] techniques [6,22,[48][49][50][51][52][53][54][55][56][57][58][59][60][61]. The addition of concurrent cisplatin-based chemotherapy has been recently incorporated in the treatment of this malignancy [62][63][64][65]. The rarity of vaginal carcinoma does not allow the planning of prospective, randomized clinical trials to define the optimal therapeutic approach.…”

Section: Treatment Modalitiesmentioning

confidence: 99%

Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors

Gadducci

Fabrini

Lanfredini

et al. 2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…5 Recently, chemoradiation has been found to improve survival in patients with advanced-stage (stages IIIYIV) PCV. 7,8 ORIGINAL STUDY…”

mentioning

confidence: 99%

Prognostic Significance of Cell Cycle- and Invasion-Related Molecular Markers and Genomic Instability in Primary Carcinoma of the Vagina

Hellman¹,

Johansson

Andersson

et al. 2013

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review

Abstract: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status.

Cited by 30 publications

References 23 publications

Concurrent Chemoradiation for Vaginal Cancer

Concurrent Chemoradiation for Vaginal Cancer

Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors

Prognostic Significance of Cell Cycle- and Invasion-Related Molecular Markers and Genomic Instability in Primary Carcinoma of the Vagina

Contact Info

Product

Resources

About